276 related articles for article (PubMed ID: 34053440)
1. Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Kumashiro S; Takagi S; Itokawa T; Tajima A; Kobayashi T; Hori Y
BMC Ophthalmol; 2021 May; 21(1):241. PubMed ID: 34053440
[TBL] [Abstract][Full Text] [Related]
2. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
3. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
5. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
6. Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking.
Horiguchi E; Takeuchi J; Tomita R; Asai K; Nakano Y; Ota H; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Sci Rep; 2022 Oct; 12(1):17032. PubMed ID: 36220845
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
8. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
9. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy.
Pichai J; Vanchalerm B; Mansing R
BMC Ophthalmol; 2021 Jan; 21(1):30. PubMed ID: 33430812
[TBL] [Abstract][Full Text] [Related]
10. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
Iacono P; Tedeschi M; Boccassini B; Chiaravalloti A; Varano M; Parravano M
Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
Hayashida M; Miki A; Honda S; Nakamura M
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
[TBL] [Abstract][Full Text] [Related]
12. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy.
Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Karasu B; Akbas YB; Aykut A; Celebi ARC
Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
[TBL] [Abstract][Full Text] [Related]
14. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
15. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.
Uetani R; Ito Y; Oiwa K; Ishikawa K; Terasaki H
Eye (Lond); 2012 May; 26(5):640-9. PubMed ID: 22573069
[TBL] [Abstract][Full Text] [Related]
16. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Demirel S; Özcan G; Yanık Ö; Batıoğlu F; Özmert E
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):905-912. PubMed ID: 30617579
[TBL] [Abstract][Full Text] [Related]
17. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
19. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the efficacy of photodynamic therapy in patients with chronic central serous chorioretinopathy.
Manethová K; Ernest J; Hrevuš M; Jirásková N
Cesk Slov Oftalmol; 2020; 75(6):298-308. PubMed ID: 32911945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
